PD-(L)1 blockade has made inroads into triple-negative breast cancer, but ER+/Her2- space is still a no go, judging by $MRK flop in Keynote-B49. From #Esmo26 via @ApexOnco -> ht

Jacob Plieth· @JacobPlieth · X·2026-10-24 15:16· 22 小时前评分70

正文 · 原文

PD-(L)1 blockade has made inroads into triple-negative breast cancer, but ER+/Her2- space is still a no go, judging by $MRK flop in Keynote-B49. From #Esmo26 via @ApexOnco -> https://www.apexonco.com/esmo-2026-keytrudas-breast-cancer-flop

520 浏览 · 2 赞 · 0 转发 · 0 回复

会议摘要

LBA51按 Proffered paper 2: Breast cancer, early and advanced stage 对上

Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)

https://esmocongress.esmo.org

来源：Jacob Plieth · x.com